There is no excerpt because this is a protected post. This content is password protected. To view it please enter your ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...

Herrmann will continue in her role as chief of staff to EVP and chief communications and public affairs officer Cristal Downing.

With a market cap of $252.6 billion, Rahway, New Jersey-based Merck & Co., Inc. (MRK) is a global leader in the healthcare ...

Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Merck & Co., Inc. in a note issued to ...

Merck (MRK) is a well-known global healthcare company that develops and sells medicines, vaccines, and animal health products. The company focuses on areas like cancer treatments, infectious diseases, ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

Merck, a leading global pharmaceutical company ... 89% of FY 2023 sales; and Animal Health, 9%. Insignificant sales occur as Other Revenue. Their core areas of focus are: diabetes, infectious ...